Publications

Citation information can be found on Google Scholar.

  1. Lazic SE (2023). Causal mediation analysis: How to avoid fooling yourself that X causes Y. Laboratory Animals (In press). [Preprint] [Github]
  2. The RIVER working group (2023). Reporting In Vitro Experiments Responsibly – the RIVER Recommendations. MetaArXiv. [LINK]
  3. Cairns J, Leonard E, Khan K, Parks C, Maglennon G, Zhang B, Lazic SE, Ewart L, David R (2023). Optimal experimental design for efficient toxicity testing in microphysiological systems: a bone marrow application. Frontiers in Pharmacology 14:1142581. [LINK]
  4. Lazic SE (2022). Genuine replication and pseudoreplication. Nature Reviews Methods Primers 2:23. [LINK] [Preprint]
  5. Lazic SE (2021). Why multiple hypothesis test corrections provide poor control of false positives in the real world. arXiv 2108.04752. [LINK] [R code]
  6. Lazic SE, Williams DP (2021). Quantifying sources of uncertainty in drug discovery predictions with probabilistic models. Artificial Intelligence in the Life Sciences 1:100004. [LINK] [Github]
  7. Semenova E, Guerriero ML, Zhang B, Hock A, Hopcroft P, Kadamur G, Afzal AM, Lazic SE (2021). Flexible fitting of PROTAC concentration-response curves with changepoint Gaussian Processes. SLAS Discovery 26(9):1212–1224.[LINK] [Github]
  8. Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Wright NA, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS (2021). Tumor genomic, transcriptomic and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Medicine 10(9):3045–3058. [LINK]
  9. Lazic SE, Williams DP (2020). Improving drug safety predictions by reducing poor analytical practices. Toxicology Research and Application 4:1–11. [LINK] [Data and code]
  10. Semenova E, Williams DP, Afzal AM, Lazic SE (2020). A Bayesian neural network for toxicity prediction. Computational Toxicology 16:100133. [LINK] [bioRxiv]
  11. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Wurbel H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 18(7):e3000410. [LINK]
  12. Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Wurbel H (2020). Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18(7):e3000411. [LINK]
  13. Lazic SE, Semenova E, Williams DP (2020). Determining organ weight toxicity with Bayesian causal models: Improving on the analysis of relative organ weights. Scientific Reports 10(1):6625. [LINK]
  14. Karp NA, Wilson Z, Stalker E, Mooney L, Lazic SE, Zhang B, Hardaker E (2020). A multi-batch design to deliver robust estimates of efficacy and reduce animal use – a syngeneic tumour case study. Scientific Reports 10(1):6178. [LINK]
  15. Lazic SE, Mellor JR, Ashby MC, Munafo MR (2020). A Bayesian predictive approach for dealing with pseudoreplication. Scientific Reports 10(1):2366. [LINK]
  16. Williams DP, Lazic SE, Foster AJ, Semenova E, Morgan P (2020). Predicting drug-induced liver injury with Bayesian machine learning. Chemical Research in Toxicology 33(1):239–248. [LINK] [Preprint] [Data and code]
  17. Adelof J, Ross JM, Lazic SE, Zetterberg M, Wiseman J, Hernebring M (2019). Conclusions from a behavioral aging study on male and female F2 hybrid mice on age-related behavior, buoyancy in water-based tests, and an ethical method to assess lifespan. Aging 11(17):7150–7168. [LINK]
  18. Barker RA, TRANSEURO consortium (2019). Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nature Medicine 25(7):1045–1053. [LINK]
  19. Foster AJ, Chouhan B, Regan SL, Rollison H, Amberntsson S, Andersson LC, Srivastava A, Darnell M, Cairns J, Lazic SE, Jang KJ, Petropolis DB, Kodella K, Rubins JE, Williams D, Hamilton GA, Ewart L, Morgan P (2019). Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid. Archives of Toxicology 93(4):1021–1037. [LINK]
  20. Lazic SE, Clarke-Williams CJ, Munafo MR (2018). Training in experimental design and statistics is essential: Response to Jordan. PLoS Biol 16(10):e3000022. [LINK]
  21. Lazic SE (2018). Four simple ways to increase power without increasing the sample size. Laboratory Animals 52(6):621–629.[LINK] [Preprint]
  22. Lazic SE, Clarke-Williams CJ, Munafo MR (2018). What exactly is 'N' in cell culture and animal experiments? PLoS Biol 6(4):e2005282. [LINK]
  23. Lazic SE, Edmunds N, Pollard CE (2018). Predicting drug safety and communicating risk: benefits of a Bayesian approach. Toxicological Sciences 162(1):89–98. [LINK] [Data and code].
  24. Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA (2017). An open label study to assess the feasibility and tolerability of Rilmenidine for the treatment of Huntington's Disease. Journal of Neurology 264(12):2457–2463. [LINK]
  25. Pollard CE, Skinner M, Lazic SE, Prior HM, Conlon KM, Valentin J-P, Dota C (2017). An analysis of the relationship between preclinical and clinical QT interval-related data. Toxicological Sciences 159(1): 94–101. [PDF]
  26. Godinez WJ, Hossian I, Lazic SE, Davies JW, Zhang X (2017). A multi-scale convolutional neural network for phenotyping high-content cellular images. Bioinformatics 33(13):2010–2019. [PDF]
  27. Lazic SE (2016). Experimental Design for Laboratory Biologists: Maximising Information and Improving Reproducibility Cambridge University Press, Cambridge, UK. [LINK]
  28. van Dijk RM, Lazic SE, Slomianka L, Wolfer DP, Amrein I (2016). Large-scale phenotyping links adult hippocampal neurogenesis to the reaction to novelty. Hippocampus 26(5):646–657. [PDF]
  29. Lazic SE (2015). Ranking, selecting, and prioritising genes with desirability functions. PeerJ 3:e1444. [LINK]
  30. Lazar AS, Panin F, Goodman AO, Lazic SE, Lazar ZI, Mason SL, Rogers L, Murgatroyd PR, Watson LP, Singh P, Borowsky B, Shneerson JM, Barker RA (2015). Sleep deficits but no metabolic deficits in premanifest Huntington's disease. Annals of Neurology 78(4):630–648. [PDF]
  31. Lazic SE (2015). Analytic strategies for the marble burying test: avoiding impossible predictions and invalid p-values. BMC Research Notes 8:141. [LINK]
  32. Naninck EF, Hoeijmakers L, Kakava-Georgiadou N, Meesters A, Lazic SE, Lucassen PJ, Korosi A (2015). Chronic early life stress alters developmental and adult neurogenesis and impairs cognitive function in mice. Hippocampus 25(3):309–28. [PDF]
  33. Lazic SE, Fuss J, Gass P (2014). Quantifying the behavioural relevance of hippocampal neurogenesis. PLoS ONE 9(11):e113855. [LINK]
  34. Walitza S, Marinova Z, Grunblatt E, Lazic SE, Remschmidt H, Vloet TD, Wendland JR (2014). Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive-compulsive disorder. Neuroscience Letters 580:100–103. [PDF]
  35. Collins LM, Lazic SE, Barker RA (2014). A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease. BMC Neurology 14:35. [LINK]
  36. Slomianka L, Drenth T, Cavegn N, Menges D, Lazic SE, Phalanndwa M, Chimimba CT, Amrein I (2013). The hippocampus of the eastern rock sengi: cytoarchitecture, markers of neuronal function, principal cell numbers, and adult neurogenesis. Frontiers in Neuroanatomy 7:34. [LINK]
  37. Lazic SE (2013). Technical comment on ``Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice.'' Science 340(6134):811. [PDF]
  38. Lazic SE, Essioux L (2013). Improving basic and translational science by accounting for litter-to-litter variation in animal models. BMC Neuroscience 14(1):37. [LINK]
  39. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7419):187–191. [LINK]
  40. Berry A, Amrein I, Notzli S, Lazic SE, Klaus F, Bellisario V, Giorgio M, Pelicci PG, Lipp HP, Cirulli F (2012). Sustained hippocampal neurogenesis in females is amplified in P66Shc-/- mice, an animal model of healthy aging. Hippocampus 22(12):2249–2259. [PDF]
  41. Urich E, Lazic SE, Molnos J, Wells I, Freskgard PO (2012). Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE 7(5):e38149. [LINK]
  42. Haller S, Schuler F, Lazic SE, Bachir-Cherif D, Kramer SD, Parrott NJ, Steiner G, Belli S (2012). Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs. Drug Metabolism and Disposition 40(8):1603–1611. [LINK]
  43. Poirier A, Belli S, Funk C, Otteneder M, Portmann R, Heinig K, Prinssen E, Lazic SE, Rayner CR, Hoffmann G, Singer T, Smith DE, Schuler F (2012). Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. Drug Metabolism and Disposition 40(8):1556–1565. [LINK]
  44. Lazic SE (2012). Using causal models to distinguish between neurogenesis-dependent and independent effects on behaviour. Journal of the Royal Society Interface 9(70):907–17. [LINK]
  45. Lazic SE (2012). Modeling hippocampal neurogenesis across the lifespan in seven species. Neurobiology of Aging 33(8):1664-1671. [PDF] [Suppl.]
  46. Kvinlaug BT, Chan W-I, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJM, Delwel R, Armstrong SA, Dohner H, Gilliland DG, Huntly BJP (2011). Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Research 71(12):4117–4129. [LINK]
  47. Lazic SE (2010). Relating hippocampal neurogenesis to behaviour: the dangers of ignoring confounding variables. Neurobiology of Aging 31:2169–2171 (discussion 2172–2175). [PDF]
  48. Lazic SE (2010). The problem of pseudoreplication in neuroscientific studies: is it affecting your analysis? BMC Neuroscience 11:5. [LINK]
  49. Lazic SE, Mason SL, Michell AW, Barker RA (2009). Visualising disease progression on multiple variables with vector plots and path plots. BMC Medical Research Methodology 9:32. [LINK]
  50. Thomas M, Tyers P, Lazic SE, Caldwell MA, Barker RA, Beazley L, Ziman M (2009). Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. Journal of Anatomy 214(3):396–405. [LINK]
  51. Lazic SE (2009). Statistical evaluation of methods for quantifying gene expression by autoradiography in histological sections. BMC Neuroscience 10(1):5. [LINK]
  52. Pinnock SB, Lazic SE, Wong HT, Wong IH, Herbert J (2009). Synergistic effects of dehydroepiandrosterone and fluoxetine on proliferation of progenitor cells in the dentate gyrus of the adult male rat. Neuroscience 158(4):1644–1651. [PDF]
  53. Lazic SE (2008). Why we should use simpler models if the data allow this: relevance for ANOVA designs in experimental biology. BMC Physiology 8:16. [LINK]
  54. Michell AW, Goodman AO, Silva AH, Lazic SE, Morton AJ, Barker RA (2008). Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. Journal of Neurology 255(8):1145–1152. [PDF]
  55. Williams BR, Lazic SE, Ogilvie RD (2008). Polysomnographic and quantitative EEG analysis of subjects with long-term insomnia complaints associated with mild traumatic brain injury. Clinical Neurophysiology 119(2):429–438. [PDF]
  56. Kvinlaug BT, Lazic SE (2008). Cancer stem cell patents. Expert Opinion on Therapeutic Patents 18(12):1405–1416. [PDF]
  57. Lazic SE, Goodman AO, Grote HE, Blakemore C, Morton AJ, Hannan AJ, van Dellen A, Barker RA (2007). Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Research 1151:219–226. [PDF]
  58. Lazic SE, Ogilvie RD (2007). Lack of efficacy of music to improve sleep: A polysomnographic and quantitative EEG analysis. International Journal of Psychophysiology 63(3):232–239. [PDF]
  59. Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, Phillips W, Barker RA (2006). Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. European Journal of Neuroscience 23(7):1829–1838. [PDF]
  60. Malhotra A, Huang Y, Fogel R, Lazic S, Pillar G, Jakab M, Kikinis R, White DP (2006). Aging and menopausal influences on pharyngeal anatomy and physiology: The predisposition to sleep apnea. American Journal of Medicine 119(1):e9–14. [PDF]
  61. Lazic SE, Barker RA (2005). Cell-based therapies for disorders of the central nervous system. Expert Opinion on Therapeutic Patents 15(10):1361–1376. [PDF]
  62. Thomas M, Lazic S, Beazley L, Ziman M (2004). Expression profiles suggest a role for Pax7 in the establishment of tectal polarity and map refinement. Experimental Brain Research 156(3):263–273. [PDF]
  63. Lazic SE, Barker RA (2003). Rapid decline in motor symptoms in HD neural transplant patients prior to surgery. Brain Research Bulletin 63(1):83–84. [PDF]
  64. Lazic SE, Grote H, Armstrong RJE, Blakemore C, Hannan AJ, van Dellen A, Barker RA (2003). Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport 15(5):811–813. [PDF]
  65. Lazic SE, Barker RA (2003). The future of cell based transplantation therapies for neurodegenerative disorders. Journal of Hematotherapy and Stem Cell Research 12(6):635–642. [PDF]